Accelerated Approval
FDA & Regulatory
Accelerated Approval lets the FDA approve a drug for a serious condition based on a surrogate endpoint reasonably likely to predict clinical benefit, with confirmatory trials required afterward. It speeds patient access but carries the risk of later withdrawal if confirmatory data disappoint.
Related terms
Track Accelerated Approval across 1,000+ biotechs
BioSniper monitors FDA decisions, clinical trials, and catalysts in real time — with evidence-backed AI analysis.
Start Free